



March 31, 2020

Company: KYORIN Holdings, Inc
Representative: Yutaka Ogihara
Representative Director, President
(Securities Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-3525-4707

Release of Novel Coronavirus Detection Reagent
“SARS-CoV-2 GeneSoC ER Kyorin”

KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara; “KYORIN Pharmaceutical”), a subsidiary of KYORIN Holdings, Inc., will release “SARS-CoV-2 GeneSoC ER Kyorin” (the “Reagent”), a novel coronavirus detection reagent using the microchannel-based genetic measurement device “GeneSoC®” (“GeneSoC®”) jointly developed with the National Institute of Advanced Industrial Science and Technology (“AIST”), by mid-April.

The Reagent is now covered by Japan’s National Health Insurance after the Tuberculosis and Infectious Diseases Control Division, Health Service Bureau, Ministry of Health, Labour and Welfare of Japan and the National Institute of Infectious Diseases listed it as a “rapid test (reverse transcription and gene amplification in less than an hour)” and published the results of its positive and negative agreement rates for novel coronavirus in their March 18, 2020 update on “2019-nCoV Genetic Testing Methods for which Results of Evaluation Using Clinical Specimens were Obtained.”

GeneSoC® is a genetic measuring device based on super-fast quantitative PCR technology which can detect novel coronavirus in around 15 minutes (excluding pre-treatment time) and which is currently being developed as a medical device. Kyorin Pharmaceutical concluded a CRO agreement with the Japan Agency for Medical Research and Development (AMED) on March 17 and provided GeneSoC® to 16 medical institutions throughout Japan for further demonstration of its accuracy as a test for novel coronavirus and verification of its operability. (Please refer to the news release of the Ministry of Economy and Trade and Industry dated March 31 for further details.)

Kyorin Pharmaceutical is putting in place the most reliable possible production system for the stable supply of the Reagent and GeneSoC® and will continue contributing to further enhancement of the testing framework for novel coronavirus infections, including shorter PCR test turnaround times, as well as to the establishment of rapid testing methods.

The impact of the release of this product on KYORIN Holdings’ consolidated operating results for the fiscal year ending March 31, 2020 is minor.